




RealRate

PHARMACEUTICAL 2021

GYRE Therapeutics INC
Rank 161 of 394

CATALYST
BIOSCIENCES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 66% points. The greatest weakness of GYRE Therapeutics INC is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 298%, being 41% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	89,510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,796
Liabilities, Non-Current	981
Other Assets	4,903
Other Compr. Net Income	-29
Other Expenses	9,163
Other Liabilities	0
Other Net Income	1,129
Other Revenues	20,948
Property and Equipment	433
Research and Development	52,975
Selling, General and Administrative Expense	16,180

Output Variable	Value in 1000 USD
Assets	94,846
Liabilities	18,777
Expenses	78,318
Revenues	20,948
Stockholders Equity	76,069
Net Income	-56,241
Comprehensive Net Income	-56,256
BaseVar	107,024
ECR before Limited Liability	193%
Economic Capital Ratio	298%